ClinicalTrials.gg
RecruitingNCT06990399PEAKUpdated May 18, 2026

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK

A Phase 3 interventional study of KSI-101 and Sham Comparator in Macular Edema Secondary to Inflammation, sponsored by Kodiak Sciences Inc. Recruiting at 56 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Kodiak Sciences Inc · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 276 studies in Macular Edema with a site in United States — 16 open to participants now, 32 under way, 11 of them phase 3. Macular Edema · United States.

Planned enrollment
19th of 244
600 · median 45
Started
2025
with 7 others
Phase 3
50 of 276
5 open now
Primary completion
2027-04
later than 17 of 31 live
Registered
263rd of 276
by date
Lead sponsor
6 of 276
Kodiak Sciences Inc

Among the 276 studies in Macular Edema with a site in United States, this one is the 19th largest by planned enrollment of the 244 interventional ones that give a count, is one of 8 that started in 2025, is one of 50 in phase 3, reaches primary completion later than 17 of the 31 other live ones, and was the 263rd registered.

Macular Edema

759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

16 of the 276 studies in Macular Edema with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Macular Edema with a site in United States, or all of them as a file.
02

Study summary

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)

03

Conditions studied

  • Macular Edema Secondary to Inflammation

Browse trials for

Keywords

  • MESI
  • macular edema
  • inflammatory macular edema
  • macular edema associated with inflammation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Macular Edema Secondary to Inflammation (MESI) with a central subfield thickness (CST) of ≥400 microns on SD-OCT in Study Eye.
  • Definitive presence of Intraretinal Fluid and/or Subretinal Fluid on SD-OCT in the Study Eye.
  • BCVA ETDRS score of ≥25 and ≤70 letters (between 20/40 and 20/320 Snellen equivalent) in the Study Eye.
  • Diagnosis of active or inactive non-infectious intraocular inflammation, acute or chronic in the Study Eye.

Exclusion criteria

Exclusion Criteria:

  • Macular Edema in the Study Eye secondary to diabetic retinopathy, RVO, or wAMD.
  • Active or suspected ocular or periocular infection in either eye.
  • Any history of or active occlusive retinal vasculitis in either eye.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    KSI-101 5 mg

    Intravitreal injection of KSI-101 5 mg once every 4 weeks for 6 monthly doses followed by individualized dosing

    Drug: KSI-101

  • Experimental
    KSI-101 10 mg

    Intravitreal injection of KSI-101 10 mg once every 4 weeks for 6 monthly doses followed by individualized dosing

    Drug: KSI-101

  • Sham comparator
    Sham

    Sham injection once every 4 weeks for 6 monthly doses followed by individualized sham dosing

    Other: Sham Comparator

Interventions

  • DrugKSI-101

    Intravitreal injection

    Also known as: tabirafusp alfa

  • OtherSham Comparator

    Sham injections

06

What researchers measure

Primary outcomes

  1. Mean change in BCVA

    Mean change in BCVA from Day 1 to the average of Week 20 and Week 24.

    Time frame: Week 24

Secondary outcomes

  1. Proportion of participants with BCVA improvement

    The proportion of participants in whom BCVA had improved by ≥15 letters from baseline to 24 weeks.

    Time frame: Baseline to 24 weeks

07

Study locations

49 of 56 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Apr 2027, 21 months after the start.

Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's planned 21 months is below that.

Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2025
First posted
May 25, 2025
StartActual
Jul 30, 2025
Primary completionEst.
Apr 2027
CompletionEst.
Nov 2027
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06990399
Lead sponsor
Kodiak Sciences Inc
Responsible party
Sponsor
First posted
May 25, 2025
Start date
Jul 30, 2025
Primary completion
Apr 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
May 18, 2026

Study contacts

Kodiak Sciences Inc
Contact
ClinicalTrials@kodiak.com
(650) 281-0850
Pablo Velazquez-Martin, MD
study director · Kodiak Sciences Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion